Hopp til innhold

Project

Health Technology Assessment of medicines, including rituximab, used for primary progressive multiple sclerosis (PPMS) - project description

Published Updated


We aim to examine the clinical and cost effectiveness of RRMS medicines in the treatment of patients with primary progressive MS.


Summary

Multiple sclerosis (MS) is an immune-mediated inflammatory disease of the central nervous system characterized by demyelination and axonal degeneration.  
According to an advisory committee on clinical trials in multiple sclerosis, MS is classified in four different categories (1) including clinical isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS).  
Currently, among all the medicines that have marketing authorization for the treatment of RRMS, only ocrelizumab has marketing authorisation for both RRMS and PPMS. 
In the present Health Technology Assessment (HTA) we aim to exam the clinical and cost effectiveness of RRMS medicines in the treatment of patients with PPMS. We will also include one medicine, rituximab, without marketing authorisation for MS. We will not assess the safety of the treatments as this is considered covered in the Health Technology Assessment of medicines used for multiple sclerosis. Part I: RRMS. 

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Torunn Elisabeth Tjelle, Norwegian Institute of Public Health

Project participants

Ingrid Kristine Ohm, Norwegian Institute of Public Health
Gunhild Hagen, Norwegian Institute of Public Health
Vida Hamidi, Norwegian Institute of Public Health
Christopher F. Rose, Norwegian Institute of Public Health
Elisabet Vivianne Hafstad, Norwegian Institute of Public Health